Biotechnological medicinal products offer great opportunities for up to now incurable diseases. Hence, they represent nowadays a significant and growing market. Nevertheless their heterogeneity still remain a big challenge. A major challenge with biopharmaceuticals is their heterogeneity. ... more
Prof. Dr. Katharina Zimmermann
Hochschule Biberach, Fakultät für Pharmazeutische Biotechnologie
Katharina Zimmermann received her Ph.D with highest honors 2001 for studying biomarkers in Alzheimer‘s disease in the DFG (German Research Foundation) graduate school “Drug Development” at Frankfurt University. This was followed by research on molecular stroke at the University of Heidelberg, and a Marie Curie Industry-Host Fellowship with Sanofi-Aventis/France, again on Alzheimer‘s. Until 2007, she worked indepently supported by grants from DFG and LECMA at Inserm in Lille/France on models of Alzheimer‘s. She supported the research and development of CNS active biopharmaceuticals at Boehringer Ingelheim since active and passive vaccination has been a consistent focus of her research. She has been appointed as Professor for Molecular Pharmacology and Biochemistry at the University of Biberach in early 2010 and teaches here Pharmaceutical Immunolgy.